Under settlement, FDA has to pre-approve Merck ads

One feature of Merck and Schering-Plough's settlement with 35 state attorneys general is a provision requiring the companies to get FDA to bless all its DTC advertisements--not just those for Vytorin, the cholesterol med that prompted the probe--before airing or publishing them. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.